Microtubule-targeting-compound PBOX-15 radiosensitizes cancer cells in vitro

Cancer Biology and Therapy

Volumn 11, Issue 4, 2011, Pages 421-428

  Forde, James C ^a,b   Maginn, Elaina N ^b   McNamara, Gillian ^a   Martin, Lynn M ^a   Campiani, Guiseppe ^d   Williams, D Clive ^c   Zisterer, Daniela ^c   McElligott, Anthony M ^b   Lawler, Mark ^b   Lynch, Thomas H ^b   Hollywood, Donal ^a   Marignol, Laure ^a  

^a Academic Unit of Clinical and Molecular Oncology   (Ireland)

^b Institute of Molecular Medicine   (Ireland)

^c ST JAMES S HOSPITAL   (Ireland)

^d UNIVERSITY OF SIENA   (Italy)

Author keywords

Chemotherapy; Hypoxia; Microtubule; Radiation

Indexed keywords

4 ACETOXY 5 (1 NAPHTHYL) NAPHTHA PYRROLO (1,4) OXAZEPINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NOCODAZOLE; PACLITAXEL; PBOX 15; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG; VINCRISTINE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL HYPOXIA; CELL KILLING; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IRRADIATION; MALE; MICROTUBULE; PROSTATE CANCER; PROTEIN EXPRESSION; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; RADIOSENSITIZATION; WESTERN BLOTTING;

AEROBIOSIS; ANOXIA; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICROTUBULES; NEOPLASMS; OXAZEPINES; PYRROLES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS;

EID: 79951826932     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.4.14183     Document Type: Article

References (52)

1. Jordan MA, Kamath K. How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 2007; 7:730-42.
2. Lee EA, Keutmann MK, Dowling ML, Harris E, Chan G, Kao GD. Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. Mol Cancer Ther 2004; 3:661-9. (Pubitemid 39193746)
3. Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm - general principles. Nat Clin Pract Oncol 2007; 4:86-100. (Pubitemid 46189538)
4. Morris PG, Fornier MN. Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 2008; 14:7167-72.
5. Mc Gee MM, Campiani G, Ramunno A, Fattorusso C, Nacci V, Lawler M, et al. Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcrabl. J Pharmacol Exp Ther 2001; 296:31-40. (Pubitemid 32015057)
6. Zisterer DM, Campiani G, Nacci V, Williams DC. Pyrrolo-1,5-benzoxazepines induce apoptosis in HL-60, Jurkat and Hut-78 cells: a new class of apoptotic agents. J Pharmacol Exp Ther 2000; 293:48-59. (Pubitemid 30180922)
7. Greene LM, Campiani G, Lawler M, Williams DC, Zisterer DM. BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1,5-benzoxazepines. Mol Pharmacol 2008; 73:419-30. (Pubitemid 351159212)
8. Mulligan JM, Greene LM, Cloonan S, Mc Gee MM, Onnis V, Campiani G, et al. Identification of tubulin as the molecular target of proapoptotic pyrrolo-1,5-benzoxazepines. Mol Pharmacol 2006; 70:60-70.
9. Nathwani SM, Butler S, Meegan MJ, Campiani G, Lawler M, Williams DC, et al. Dual targeting of tumour cells and host endothelial cells by novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines. Cancer Chemother Pharmacol 2009; In press.
10. Greene LM, Fleeton M, Mulligan J, Gowda C, Sheahan BJ, Atkins GJ, et al. The pyrrolo-1,5-benzoxazepine, PBOX-6, inhibits the growth of breast cancer cells in vitro independent of estrogen receptor status and inhibits breast tumour growth in vivo. Oncol Rep 2005; 14:1357-63.
11. Bright SA, McElligott AM, O'Connell JW, O'Connor L, Carroll P, Campiani G, et al. Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro in ex vivo patient samples and in vivo. Br J Cancer 2010; 102:1474-82.
12. McElligott AM, Maginn EN, Greene LM, McGuckin S, Hayat A, Browne PV, et al. The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia. Cancer Res 2009; 69:8366-75.
13. Bright SA, Greene LM, Greene TF, Campiani G, Butini S, Brindisi M, et al. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells. Biochem Pharmacol 2009; 77:310-21.
14. Nathwani SM, Butler S, Fayne D, McGovern NN, Sarkadi B, Meegan MJ, et al. Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells. Cancer Chemother Pharmacol 66:585-96.
15. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994; 13:139-68. (Pubitemid 24220002)
16. Skvortsova I, Skvortsov S, Haidenberger A, Devries A, Nevinny-Stickel M, Saurer M, et al. Effects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in vitro. J Chemother 2004; 16:372-80. (Pubitemid 39049888)
17. Thews O, Gassner B, Kelleher DK, Schwerdt G, Gekle M. Impact of hypoxic and acidic extracellular conditions on cytotoxicity of chemotherapeutic drugs. Adv Exp Med Biol 2007; 599:155-61.
18. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008; 8:180-92.
19. Chresta CM, Masters JR, Hickman JA. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res 1996; 56:1834-41. (Pubitemid 26118219)
20. Moeller BJ, Dewhirst MWy. Raising the bar: how HIF-1 helps determine tumor radiosensitivity. Cell Cycle 2004; 3:1107-10. (Pubitemid 40268623)
21. Adams JM, Difazio LT, Rolandelli RH, Lujan JJ, Hasko G, Csoka B, et al. HIF-1: a key mediator in hypoxia. Acta Physiol Hung 2009; 96:19-28.
22. Liu L, Ning X, Sun L, Shi Y, Han S, Guo C, et al. Involvement of MGr1-Ag/37LRP in the vincristine-induced HIF-1 expression in gastric cancer cells. Mol Cell Biochem 2007; 303:151-60. (Pubitemid 47261312)
23. Zeng L, Kizaka-Kondoh S, Itasaka S, Xie X, Inoue M, Tanimoto K, et al. Hypoxia inducible factor-1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions. Cancer Sci 2007; 98:1394-401. (Pubitemid 47241762)
24. Escuin D, Kline ER, Giannakakou P. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1 alpha accumulation and activity by disrupting microtubule function. Cancer Res 2005; 65:9021-8. (Pubitemid 41377394)
25. Chopra S, Foltz WD, Milosevic MF, Toi A, Bristow RG, Menard C, et al. Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: a pilot study in men with prostate cancer. Int J Radiat Biol 2009; 85:805-13.
26. Petrylak DP. Chemotherapy for androgen-independent prostate cancer. Semin Urol Oncol 2002; 20:31-5. (Pubitemid 35001518)
27. Burhans WC, Heintz NH. The cell cycle is a redox cycle: linking phase-specific targets to cell fate. Free Radic Biol Med 2009; 47:1282-93.
28. Blagosklonny MV. Cell senescence: hypertrophic arrest beyond the restriction point. J Cell Physiol 2006; 209:592-7. (Pubitemid 44665674)
29. Marignol L, Coffey M, Lawler M, Hollywood D. Hypoxia in prostate cancer: A powerful shield against tumour destruction? Cancer Treat Rev 2008; 34:313-27.
30. Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Greenberg RE, Stobbe C, et al. Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology 2002; 60:634-9. (Pubitemid 35246449)
31. Rudolfsson SH, Bergh A. Hypoxia drives prostate tumour progression and impairs the effectiveness of therapy, but can also promote cell death and serve as a therapeutic target. Expert Opin Ther Targets 2009; 13:219-25.
32. Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 2008; 9:342-51.
33. Foley R, Marignol L, Thomas AZ, Cullen IM, Perry AS, Tewari P, et al. The HIF-1 alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers. Cancer Biol Ther 2009; 8:118-24.
34. Movsas B, Chapman JD, Horwitz EM, Pinover WH, Greenberg RE, Hanlon AL, et al. Hypoxic regions exist in human prostate carcinoma. Urology 1999; 53:11-8. (Pubitemid 29016607)
35. Mikheev AM, Mikheev SA, Zhang Y, Aebersold R, Zarbl H. CArG binding factor A (CBF-A) is involved in transcriptional regulation of the rat Ha-ras promoter. Nucleic Acids Res 2000; 28:3762-70.
36. Koritzinsky M, Seigneuric R, Magagnin MG, van den Beucken T, Lambin P, Wouters BG. The hypoxic proteome is influenced by gene-specific changes in mRNA translation. Radiother Oncol 2005; 76:177-86. (Pubitemid 41725445)
37. Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S, et al. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1α, HIF-2α and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 2005; 11:7658-63. (Pubitemid 41611607)
38. Chun YS, Lee KH, Choi E, Bae SY, Yeo EJ, Huang LE, et al. Phorbol ester stimulates the nonhypoxic induction of a novel hypoxia-inducible factor 1 alpha isoform: implications for tumor promotion. Cancer Res 2003; 63:8700-7. (Pubitemid 38064047)
39. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 2001; 12:363-9. (Pubitemid 32685637)
40. Zhong XS, Zheng JZ, Reed E, Jiang BH. SU5416 inhibited VEGF and HIF-1 alpha expression through the PI3K/AKT/p70S6K1 signaling pathway. Biochem Biophys Res Commun 2004; 324:471-80. (Pubitemid 39345542)
41. Yacoub A, Gilfor D, Hawkins W, Park MA, Hanna D, Hagan MP, et al. MEK1/2 inhibition promotes Taxotere lethality in mammary tumors in vivo. Cancer Biol Ther 2006; 5:1332-9. (Pubitemid 44772260)
42. Le XF, Lammayot A, Gold D, Lu Y, Mao W, Chang T, et al. Genes affecting the cell cycle, growth, maintenance and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 2005; 280:2092-104.
43. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004; 23:2825-37. (Pubitemid 38638845)
44. Magnon C, Opolon P, Ricard M, Connault E, Ardouin P, Galaup A, et al. Radiation and inhibition of angiogenesis by canstatin synergize to induce HIF-1 alpha-mediated tumor apoptotic switch. J Clin Invest 2007; 117:1844-55. (Pubitemid 47036318)
45. Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS. Hypoxia-inducible factor 1 alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol 2003; 23:359-69. (Pubitemid 36008526)
46. Moeller BJ, Dreher MR, Rabbani ZN, Schroeder T, Cao Y, Li CY, et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 2005; 8:99-110. (Pubitemid 41132739)
47. Luk CK, Sutherland RM. Nutrient modification of proliferation and radiation response in EMT6/Ro spheroids. Int J Radiat Oncol Biol Phys 1987; 13:885-95. (Pubitemid 17096727)
48. Herscher LL, Cook J. Taxanes as radiosensitizers for head and neck cancer. Curr Opin Oncol 1999; 11:183-6. (Pubitemid 29229611)
49. Supiot S, Hill RP, Bristow RG. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther 2008; 7:993-9. (Pubitemid 351551053)
50. Campiani G, Nacci V, Fiorini I, De Filippis MP, Garofalo A, Ciani SM, et al. Synthesis, biological activity and SARs of pyrrolobenzoxazepine derivatives, a new class of specific "peripheral-type" benzodiazepine receptor ligands. J Med Chem 1996; 39:3435-50.
51. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994; 91:8802-6.
52. Palayoor ST, Tofilon PJ, Coleman CN. Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha in prostate cancer cells. Clin Cancer Res 2003; 9:3150-7. (Pubitemid 37006311)